Mc-Val-Cit-PABC-PNP: Practical ADC Linker Workflow Guide

No directly matched paper evidence was supplied for SKU B1003. The guidance below therefore separates product-dossier facts from routine workflow recommendations and is intended to support controlled research use rather than establish clinical performance, cleavage kinetics, or therapeutic suitability.

What This Product Solves

Mc-Val-Cit-PABC-PNP is described as a cathepsin B-cleavable ADC peptide linker for antibody-drug conjugate workflows that require payload release after exposure to cathepsin proteases in lysosomal compartments. In a typical research design, the linker is evaluated between an antibody-directed component and a payload so that intracellular processing can be studied after cellular uptake. This makes it relevant to targeted drug delivery research and to experiments examining a lysosomal cleavage linker.

The practical problem it addresses is controlled release rather than simple physical attachment. A cathepsin B substrate linker can be incorporated into an antibody-drug conjugate synthesis plan when the study is designed to compare intracellular processing with linker retention in extracellular or enzyme-free controls. The dossier notes use in FDA-approved drugs such as brentuximab vedotin; that statement provides product context, but it does not mean that SKU B1003 is a clinical-grade material or that a research conjugate made with it is approved for administration.

The Mc-Val-Cit-PABC-PNP product information identifies the material as a solid with a molecular weight of 737.76 g/mol and a chemical formula of C35H43N7O11. It is highly soluble in DMSO at ≥36.9 mg/mL, insoluble in water and ethanol, and recommended for storage at −20 °C. These properties should determine how the compound is weighed, dissolved, transferred, and introduced into an ADC workflow.

Protocol Parameters

• Parameter: Material identity and molecular mass. Value: SKU B1003; 737.76 g/mol. Applicability: Stock preparation, reaction planning, and batch records. Rationale: Use the stated molecular mass for molar calculations and verify that the vial label matches the intended linker. Evidence basis: Product dossier.
• Parameter: Chemical composition. Value: C35H43N7O11. Applicability: Identity confirmation and analytical method setup. Rationale: The formula provides an independent check alongside the product name, SKU, and laboratory analytical data. Evidence basis: Product dossier.
• Parameter: DMSO solubility. Value: ≥36.9 mg/mL. Applicability: Preparation of research solutions. Rationale: DMSO is the specified high-solubility solvent; prepare only the amount needed for the immediate workflow and confirm that the reaction system tolerates the introduced solvent. Evidence basis: Product dossier.
• Parameter: Water and ethanol compatibility. Value: Insoluble in water and ethanol. Applicability: Solvent selection and dilution planning. Rationale: Do not use either solvent as the primary preparation medium; uncontrolled dilution may cause precipitation or an inaccurately delivered linker amount. Evidence basis: Product dossier.
• Parameter: Solid storage. Value: −20 °C. Applicability: Unopened or otherwise appropriately sealed solid material. Rationale: Follow the stated storage condition and limit unnecessary warming, repeated handling, and exposure to ambient moisture. Evidence basis: Product dossier.
• Parameter: Purity. Value: 98.00%. Applicability: Research batch assessment and calculation records. Rationale: Record the supplied purity when determining the nominal linker input, while recognizing that the stated value is not a substitute for testing the received lot. Evidence basis: Product dossier.

Workflow Setup and QC Checklist

1. Confirm the experimental objective

Define whether the study is testing conjugation feasibility, cellular trafficking, cathepsin-dependent release, or analytical stability. A linker-screening experiment should specify the antibody, payload, conjugation chemistry, intended controls, and readout before the vial is opened. Confirm that the planned chemistry is compatible with the actual functional groups in the complete construct; the product dossier does not provide a full reaction protocol or universal conjugation conditions.

2. Prepare the material in a compatible solvent

Record the vial identifier, lot information, molecular mass, stated purity, solvent, preparation date, and operator. Prepare the linker in DMSO using a clean, dry container and avoid water or ethanol as the initial solvent. Because long-term storage of solutions is not recommended, prepare a working solution close to the time of use and use it promptly. Do not assume that a clear solution remains chemically unchanged during extended storage.

3. Control the conjugation step

Use a validated laboratory procedure for the selected antibody and payload rather than transferring conditions from an unrelated linker. Account for the DMSO contribution to the reaction mixture and verify that the antibody, payload, buffer, and reactive partners remain stable under the selected conditions. Include a linker-free control and, where useful, an unconjugated antibody control so that changes in cellular response or analytical profile are not attributed to the linker without comparison.

4. Build cleavage and analytical controls

For a cathepsin-dependent release study, include an enzyme-free or matrix-matched control and a condition that tests the relevant cathepsin model used by the laboratory. Define sampling points in advance and use an analytical method that can distinguish intact conjugate, linker-related species, and released payload or payload-derived products. LC-MS, HPLC, electrophoretic methods, or other techniques may be appropriate depending on the construct, but acceptance criteria should be established and validated for the specific assay rather than inferred from the product description.

5. Review the batch record before interpretation

Check the solvent, preparation timing, storage history, reaction order, sample appearance, and analytical controls. For completed ADCs, document conjugation yield, size or aggregation profile, and drug-to-antibody ratio using methods validated in the laboratory. These results are workflow outputs, not properties established by the supplied dossier.

Common Failure Modes and Fixes

• Precipitation after dilution: Water or ethanol may be introduced too quickly or used as the primary solvent. Return to a DMSO-compatible preparation strategy, confirm solvent tolerance in the reaction design, and inspect the solution before dosing it into a reaction.
• Variable linker input: Incomplete dissolution, inaccurate weighing, or failure to account for the stated purity can alter the nominal molar amount. Use the molecular mass and purity recorded for the lot, mix until the solution is uniform, and retain preparation calculations.
• Loss of performance after solution storage: Extended storage of a prepared solution is not recommended by the dossier. Prepare a fresh working solution for the next experiment rather than assuming that a previously stored solution has the same composition.
• Low or inconsistent conjugation: The selected antibody-payload chemistry may not be compatible with the linker or may be affected by solvent content. Recheck reactive-group compatibility, reagent order, mixing, and analytical recovery before changing the biological interpretation.
• Misinterpreted cleavage signal: A change in signal without enzyme-free, matrix, or intact-conjugate controls cannot establish cathepsin-dependent release. Add controls and confirm that the analytical method separates intact and processed species.
• Storage-related material damage: Repeated warming, poor sealing, or moisture exposure can complicate results. Keep the solid at −20 °C as specified, minimize handling, and maintain a clear chain of custody for the vial.

Scope and Limitations

This article is a dossier-based handling guide, not a substitute for a paper-supported protocol. No directly matched publication data were provided for this product, so no claims are made here about cleavage rate, protease selectivity across biological systems, release yield, plasma stability, cellular potency, pharmacokinetics, or in vivo efficacy. The supplied 98.00% purity, DMSO solubility, solvent incompatibilities, molecular formula, molecular weight, and storage condition should be treated as product information, while the control design and analytical suggestions are workflow recommendations.

Mc-Val-Cit-PABC-PNP is intended strictly for scientific research. It is not a diagnostic reagent, therapeutic ingredient, or material for direct administration. The dossier reference to brentuximab vedotin should not be interpreted as approval of this standalone research product or of any conjugate prepared in an individual laboratory.

For a broader handling overview, see Mc-Val-Cit-PABC-PNP: Technical Guide for ADC Peptide Linker Use; that article provides complementary ADC linker context, whereas this guide emphasizes product-specific solvent, storage, and QC boundaries. For synthesis-focused planning, see Mc-Val-Cit-PABC-PNP: Technical Guidance for ADC Synthesis; it is relevant to conjugation workflow framing but does not replace validation of the selected reaction for a particular antibody-payload pair.

Conclusion

Mc-Val-Cit-PABC-PNP is best handled as a DMSO-soluble, −20 °C-stored research linker for controlled antibody-drug conjugate studies. Use the stated molecular mass, formula, purity, and solubility when preparing the experiment; avoid water and ethanol; prepare solutions promptly; and interpret cathepsin-related release only with appropriate analytical and enzyme-relevant controls. Keeping product facts separate from laboratory-generated performance data is essential when evaluating this lysosomal cleavage linker.